Loading…
Can-Fite BioPharma Ltd. is projected to decline to $3.34 by 2027, a 0% move from its current price of $3.35. CANF is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.23 | $3.35 | $3.47 | -0.05% |
| May 30 | $3.18 | $3.35 | $3.52 | -0.10% |
| May 31 | $3.15 | $3.34 | $3.55 | -0.16% |
| Jun 1 | $3.12 | $3.34 | $3.59 | -0.21% |
| Jun 2 | $3.09 | $3.34 | $3.61 | -0.26% |
| Jun 3 | $3.06 | $3.34 | $3.64 | -0.31% |
| Jun 4 | $3.04 | $3.34 | $3.66 | -0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.04 | $3.34 | $3.66 | -0.36% |
| Week 2 | $2.92 | $3.33 | $3.79 | -0.72% |
| Week 3 | $2.82 | $3.31 | $3.89 | -1.08% |
| Week 4 | $2.74 | $3.30 | $3.98 | -1.44% |
| Week 5 | $2.67 | $3.29 | $4.05 | -1.80% |
| Week 6 | $2.61 | $3.28 | $4.12 | -2.15% |
| Week 7 | $2.55 | $3.27 | $4.18 | -2.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for cancer, liver inflammatory diseases, and erectile dysfunction in Israel. Its leadership in the field is highlighted by a pipeline that includes Piclidenoson, which has completed Phase III clinical trial for the treatment of psoriasis, and Namodenoson, in Phase III for the treatment of liver cancer, Phase IIa for the treatment of pancreatic cancer, and Phase IIb trial for metabolic associated steatohepatitis.
CF602 is in pre-clinical trial for the treatment of erectile dysfunction. The company also offers cannabinoids for conditions associated with elevated expression of the A3 adenosine receptors and develops a commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson.
Can-Fite was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
CANF is a healthcare stock trading with a current price of $3.40 and a market capitalization of $7.28M, ranking 5246 by market cap. The asset operates within the pharmaceutical/biotech sector as a clinical-stage company with a pipeline spanning psoriasis, liver cancer, pancreatic cancer, and metabolic liver conditions, plus pre-clinical programs.
A major floor 23.3% below — a decisive break under it would weaken the trend.
The nearest floor, 13.1% below — buyers have tended to step in here.
The nearest ceiling, 8.7% above — a clean break opens room to run.
A major ceiling 79.7% above — clearing it would confirm fresh momentum.
Key CANF support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CANF market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.42 | Sell | $3.39 | Sell |
| MA 10 | $3.41 | Sell | $3.39 | Sell |
| MA 20 | $3.36 | Sell | $3.34 | Buy |
| MA 50 | $3.19 | Buy | $3.45 | Sell |
| MA 100 | $3.76 | Sell | $4.39 | Sell |
| MA 200 | $6.73 | Sell | $8.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.70 | Neutral |
| Stoch RSI (14) | 17.07 | Buy |
| CCI (20) | -4.61 | Neutral |
| Williams %R (14) | -74.36 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -4.56 | Sell |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 25.64 | Neutral |
| TRIX (15) | 0.26 | Buy |
| Awesome (5,34) | 0.22 | Buy |
| Ultimate (7,14,28) | 50.09 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 3.43 | Sell |
| ADX (14) | 12.39 | Neutral |
| ATR (14) | 0.11 | Info |
Technically, the near-term picture shows a bullish sentiment overall. The RSI14 sits at 50, and the price is above the 50-day simple moving average of $3.20, with the 200-day simple moving average at $6.84. Immediate support is pegged at $2.91 and resistance at $3.64.
Over the last 30 days, the price has traded between $2.67 and $4.34, indicating a modestly wide range. The stock also carries an annualized volatility of 70%, suggesting heightened price movement relative to many equities.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.91 | $3.35 | $4.55 | 0% | Neutral | |
| $2.58 | $3.34 | $4.63 | 0% | Neutral | |
| $3.27 | $4.40 | $6.37 | +31% | Bullish | |
| $3.56 | $4.93 | $7.40 | +47% | Bullish | |
| $3.46 | $4.93 | $7.62 | +47% | Bullish | |
| $3.35 | $4.90 | $7.76 | +46% | Bullish | |
| $3.12 | $4.66 | $7.56 | +39% | Bullish | |
| $3.20 | $4.90 | $8.10 | +46% | Bullish | |
| $3.38 | $5.28 | $8.89 | +58% | Bullish | |
| $3.90 | $6.22 | $10.66 | +86% | Bullish | |
| $3.79 | $6.64 | $12.25 | +98% | Bullish | |
| $7.45 | $15.49 | $31.73 | +362% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.91 | $3.35 | $3.92 | +0.00% |
| June 2026 | $2.67 | $3.15 | $3.83 | -5.90% |
| July 2026 | $2.67 | $3.20 | $3.95 | +1.36% |
| August 2026 | $2.80 | $3.37 | $4.22 | +5.53% |
| September 2026 | $2.76 | $3.35 | $4.23 | -0.74% |
| October 2026 | $2.70 | $3.30 | $4.21 | -1.46% |
| November 2026 | $2.80 | $3.45 | $4.44 | +4.47% |
| December 2026 | $2.84 | $3.51 | $4.55 | +1.78% |
Click any year to see its month-by-month CANF forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Can-Fite BioPharma Ltd.'s 2026 outlook centres on $3.35, within a $2.91 to $4.55 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CANF could reach as high as $4.63, with a base case around $3.34 and support toward $2.58 — roughly 0% from $3.35. Price action looks broadly range-bound.
Expect CANF to range from $3.27 to $6.37 through 2028. The $4.40 average target implies a +31% move from current prices. That is up +32% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CANF price prediction for 2029 points to an average of $4.93 (low $3.56, high $7.40) — a potential gain of +47% on today's $3.35. Momentum favours further upside here.
In 2030, CANF is projected to trade between $3.46 and $7.62, averaging $4.93 — a potential gain of +47% from today's $3.35. That is 0% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
Can-Fite BioPharma Ltd.'s 2031 outlook centres on $4.90, within a $3.35 to $7.76 range. That is -1% versus the projected 2030 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2032, CANF could reach as high as $7.56, with a base case around $4.66 and support toward $3.12 — roughly +39% from $3.35. Buyers look set to stay in control over this stretch.
Expect CANF to range from $3.20 to $8.10 through 2033. The $4.90 average target implies a +46% move from current prices. That is up +5% on the projected 2032 average. Momentum favours further upside here.
The CANF price prediction for 2034 points to an average of $5.28 (low $3.38, high $8.89) — a potential gain of +58% on today's $3.35. Buyers look set to stay in control over this stretch.
In 2035, CANF is projected to trade between $3.90 and $10.66, averaging $6.22 — a potential gain of +86% from today's $3.35. That is up +18% on the projected 2034 average. Momentum favours further upside here.
Can-Fite BioPharma Ltd.'s 2040 outlook centres on $6.64, within a $3.79 to $12.25 range. That is up +7% on the projected 2035 average. That marks a +98% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CANF could reach as high as $31.73, with a base case around $15.49 and support toward $7.45 — roughly +362% from $3.35. Momentum favours further upside here.
Investing $1,000 in CANF today (≈ 298.507463 CANF) could be worth
$4,623.32
+$3,623.32 (+362%) by 2050 · US Dollar
Based on the average projected CANF price of $15.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CANFwould be worth at today's price.
$1,000 invested in CANF on May 27, 2025 (≈ 46.728973 CANF) would be worth
$156.54
-$843.46 (-84.3%) today · 0.16× · US Dollar
Based on a CANF entry price of $21.4 vs. today's $3.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.46 | $968.21 | -3.2% |
| 1 month ago | $2.92 | $1,147.26 | +14.7% |
| 3 months ago | $4.93 | $679.51 | -32.0% |
| 6 months ago | $7 | $478.57 | -52.1% |
| 1 year ago | $21.4 | $156.54 | -84.3% |
| All time (5.0y) ago | $426 | $7.86 | -99.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CANF forecast.
Our base-case forecast reaches $6.70 around 2050.
Implied market cap at $6.70: $14.36M
The multi-year forecast exhibits meaningful upside, with 2026 averaging $3.40 and reaching higher levels in subsequent years. Specifically, the forecast shows 2028 averaging $4.62, 2029 averaging $5.12, 2030 averaging $5.08 (ROI 49.4%), 2031 averaging $5.11, 2032 averaging $4.80, 2033 averaging $5.05, 2034 averaging $5.55, and 2035 averaging $6.49. The horizon extends to 2040 with an average of $6.98 (ROI 105.4%) and culminates in 2050 with an average of $16.28 (ROI 378.7%).
The sentiment remains BULLISH across many forecast years, with notable peaks in 2040 and 2050.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $5.08 with a min of $3.52 and a max of $7.95, with a forecasted ROI of 49.4% and a bullish sentiment.
Forecasts show a mix of neutral to bullish sentiment across years, with 2028–2035 exhibiting rising averages and a 2050 average of $16.28 and a max of $34.08, supporting a bullish longer-term view, but these are estimates, not guarantees.
Yes. The forecast lists a max of $34.08 in 2050 with a projected ROI of 378.7% and a bullish sentiment.
CANF's current price is $3.40.
RSI14 is 50, the SMA50 is $3.20, the SMA200 is $6.84, with support at $2.91 and resistance at $3.64. The 30-day range is $2.67 to $4.34, and annualized volatility is 70%.
Can-Fite BioPharma Ltd. Community Discussion
0Share your Can-Fite BioPharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.